A股異動 | 遼寧成大漲停 韶關高騰成第一大股東疊加公司開展新冠肺炎疫苗研製
格隆匯2月10日丨遼寧成大(600739.SH)漲停,報17.64元,暫成交3.4億元,最新總市值270億。公司昨日公告稱,股東新華聯控股擬將所持7927.2萬股(佔公司總股本的5.18%)轉讓予韶關高騰,轉讓價格為16.9元/股。完成後,韶關高騰將成為第一大股東。此外,中國疫苗行業協會2月9日發佈消息,包括遼寧成大在內的17家會員單位正在開展新型冠狀病毒感染的肺炎疫苗的研製工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.